{"id":"W2805341297","doi":"10.1016/s1470-2045(18)30354-1","title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Amgen","keywords":"Carfilzomib; Medicine; Dosing; Refractory (planetary science); Interim analysis; Interim; Multiple myeloma; Lenalidomide; Internal medicine; Oncology; Clinical trial; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003123479,0.001334468,0.004096191,0.0003769639,0.0004699138,0.001292553,0.000916494,0.001797736,0.003422091],"category_scores_gemma":[0.002596003,0.0006298813,0.003325439,0.0004861741,0.0008554299,0.001224464,0.0004090636,0.003517363,0.0008487109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006649018,"about_ca_system_score_gemma":0.0008171915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001001661,"about_ca_topic_score_gemma":0.001797611,"domain_scores_codex":[0.9987994,0.0006883629,0.00006435695,0.0001391215,0.00009985363,0.0002087107],"domain_scores_gemma":[0.9983389,0.0006304285,0.0003859972,0.0002240073,0.00008142207,0.0003392402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9708169,0.002662667,0.000640439,0.0002953859,0.001259229,0.00002971431,0.00005069318,0.0005646241,0.002403648,0.0000704859,0.0008135338,0.02039276],"study_design_scores_gemma":[0.8788586,0.1089412,0.007744638,0.00004825475,0.001816381,0.00005792989,0.00003199052,0.0007711348,0.0007086393,0.0003160932,0.0006692745,0.00003586091],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898935,0.005066142,0.0006079135,0.0007278746,0.0005059399,0.0007346991,0.0008109496,0.0001604679,0.001492507],"genre_scores_gemma":[0.9915316,0.001653812,0.001371878,0.0009575949,0.000394945,0.00103031,0.000848018,0.00004382055,0.002168027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004096191,"threshold_uncertainty_score":0.01651871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05709115066878615,"score_gpt":0.3817391800709356,"score_spread":0.3246480294021494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}